Erlotinib: applications in therapy and current status of research

References

• Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol.14, 737–744 (1996).
   PubMed Web of Science ®Google Scholar
• Vermorken J, Mesia R, Vega V et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy – results of a randomized Phase III (extreme) study. Proc. Am. Soc. Clin. Oncol.25 (2007) (Abstract 6091).
   Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol.26, 2311–2319 (2008).
   PubMed Web of Science ®Google Scholar
• Pirker R, Szczesna A, von Pawel J et al. FLEX: a randomized, multicenter, Phase III study of cetuximab in combination with cisplatin/vinorelbine versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer. J. Clin. Oncol.26(Suppl.), (2008) (Abstract 3).
   PubMedGoogle Scholar
• Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol.25, 1658–1664 (2007).
   PubMed Web of Science ®Google Scholar
• Crawford J, Sandler AB, Hammond LA et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer. J. Clin. Oncol.22(Suppl. 14), (2004) (Abstract 7083).
   Google Scholar
• Hecht JR, Mitchell E, Chidiac T et al. An updated analysis of safety and efficacy of oxaliplatin/bevacizumab +/- panitumumab for first-line treatment of metastatic colorectal cancer from a randomized, controlled trial (PACCE). Presented at: 2008 Gastrointestinal Cancers Symposium. Orlando, FL, USA 25–27 January, 2008 (Abstract 273).
   Google Scholar
• Saltz LB, Meropol NJ, Loehrer PJ et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol.22, 1201–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351, 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol.23, 1803–1810 (2005).
   PubMed Web of Science ®Google Scholar
• van Cutsem E, Lang I, D’haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J. Clin. Oncol.26(Suppl.), (2008) (Abstract 2).
   Web of Science ®Google Scholar
• Cohen S, Carpenter G, King L. Epidermal growth factor-receptor-protein kinase interactions: Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J. Biol. Chem.255, 4834–4842 (1980).
   PubMed Web of Science ®Google Scholar
• Wells A. Molecules in focus: EGF receptor. Int. J. Biochem. Cell Biol.31, 637–643 (1999).
   PubMed Web of Science ®Google Scholar
• Threadgill DW, Dlugosz AA, Hansen LA et al. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science269, 230–234 (1995).
   PubMed Web of Science ®Google Scholar
• Du X, Tabeta K, Hoebe K et al. Velvet, a dominant EGFR mutation that causes wavy hair and defective eyelid development in mice. Genetics166, 331–340 (2004).
   Google Scholar
• Ullrich A, Coussens L, Hayflick JS et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature309, 418–425 (1984).
   PubMed Web of Science ®Google Scholar
• Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem.277, 46265–46272 (2002).
   PubMed Web of Science ®Google Scholar
• Tzahar E, Waterman H, Chen X et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell Biol.16, 5276–5287 (1996).
   PubMed Web of Science ®Google Scholar
• Schreiber AB, Winkler ME, Derynck R. Transforming growth factor-α: a more potent angiogenic mediator than epidermal growth factor. Science232, 1250–1253 (1986).
   PubMed Web of Science ®Google Scholar
• Gorden P, Carpentier J-L, Cohen S et al. Epidermal growth factor: morphological demonstration of binding, internalization, and lysosomal association in human fibroblasts. Proc. Natl Acad. Sci. USA75(10), 5025–5029 (1978).
   PubMed Web of Science ®Google Scholar
• Hanover JA, Willingham MC, Pastan I. Kinetics of transit of transferrin and epidermal growth factor through clathrin-coated membranes. Cell39, 283–293 (1984).
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell103, 211–225 (2000).
   PubMed Web of Science ®Google Scholar
• Perry JE, Grossman ME, Tindall DJ. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate35, 117–124 (1998).
   PubMed Web of Science ®Google Scholar
• Wells A. Tumour invasion: role of growth factor-induced cell motility. Adv. Cancer Res.78, 31–101 (2000).
   PubMed Web of Science ®Google Scholar
• Verbeek BS, Adriaansen-Slot SS, Vroom TM et al. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett.425, 145–150 (1998).
   PubMed Web of Science ®Google Scholar
• Price JT, Wilson HM, Haites NE. Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Eur. J. Cancer32(11), 1977–1982 (1996).
   Google Scholar
• Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell Biol.17, 1595–1606 (1997).
   PubMed Web of Science ®Google Scholar
• Graus-Porta D, Beerli RR, Daly JM et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J.16, 1647–1655 (1997).
   PubMed Web of Science ®Google Scholar
• Fedi P, Pierce J, Di Fiore PP et al. Efficient coupling of phosphatidylinositol 3-kinase, but not phospholipase C-γ or GTPase-activating protein distinguishes ErbB3 signalling from that of other ErbB/EGFR family members. Mol. Cell Biol.14, 492–500 (1994).
   PubMed Web of Science ®Google Scholar
• Pinkas-Kramarski R, Soussan L, Waterman H et al. Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J.15, 2452–2467 (1996).
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol.19, 183–232 (1995).
   PubMed Web of Science ®Google Scholar
• Ishitoya J, Toriyama M, Oguchi N et al. Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. Br. J. Cancer59, 559–562 (1989).
   PubMed Web of Science ®Google Scholar
• Chung CH, Ely K, McGavran L et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinoma. J. Clin. Oncol.24, 4170–4176 (2006).
   PubMed Web of Science ®Google Scholar
• Fujino S, Enokibori T, Tezuka N et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur. J. Cancer32A, 2070–2074 (1996).
   PubMed Web of Science ®Google Scholar
• Brabender J, Danenberg KD, Metzger R et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res.7, 1850–1855 (2001).
   PubMed Web of Science ®Google Scholar
• Rusch V, Klimstra D, Venkatraman E et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res.3, 515–522 (1997).
   PubMed Web of Science ®Google Scholar
• Koenders PG, Beex LVAM, Geurts-Moespot A et al. Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res.51, 4544–4548 (1991).
   PubMed Web of Science ®Google Scholar
• Gross ME, Zorbas MA, Danels YJ et al. Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res.51, 1452–1459 (1991).
   PubMed Web of Science ®Google Scholar
• Buckley A, Burgart L, Sahai V et al. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am. J. Clin. Pathol.129, 245–251 (2008).
   Google Scholar
• Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur. J. Cancer37, S9–S15 (2001).
   PubMedGoogle Scholar
• Radinsky R, Risin S, Fan D et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin. Cancer Res.1, 19–31 (1995).
   PubMed Web of Science ®Google Scholar
• Rubin Grandis J, Melham MF, Gooding WE et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl Cancer Inst.90, 824–832 (1998).
   PubMed Web of Science ®Google Scholar
• Bartlett JM, Langdon SP, Simpson BJ et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer73, 301–306 (1996).
   PubMed Web of Science ®Google Scholar
• Osaki A, Toi M, Yamada H et al. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am. J. Surg.164, 323–326 (1992).
   PubMed Web of Science ®Google Scholar
• Jacot W, Pujol J-L, Boher J-M et al. Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer. Br. J. Cancer91, 430–433 (2004).
   Google Scholar
• D’Amico TA, Massey M, Herndon II JE et al. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J. Thorac. Cardiovasc. Surg.117, 736–743 (1999).
   PubMed Web of Science ®Google Scholar
• Meert A-P, Martin B, Delmotte P et al. The role of EGF-R expression on patient survival in lung cacner: A systematic review with meta-analysis. Eur. Respir. J.20, 975–981 (2002).
   PubMed Web of Science ®Google Scholar
• Moyer JD, Barbacci EG, Iwata KK et al. Induction of apoptosis and cell cycle arrest by OSI-774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res.57, 4838–4848 (1997).
   PubMed Web of Science ®Google Scholar
• Tracy S, Mukohara T, Hansen M et al. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res.64, 7241–7244 (2004).
   PubMed Web of Science ®Google Scholar
• Gong Y, Somwar R, Politi K et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med.4, 1655–1668 (2007).
   Google Scholar
• Huether A, Hopfner M, Sutter AP et al. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J. Hepatol.43, 661–669 (2005).
   PubMed Web of Science ®Google Scholar
• Dai Q, Ling Y-H, Lia M et al. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin. Cancer Res..11, 1572–1578 (2005).
   PubMed Web of Science ®Google Scholar
• Pollack VA, Savage DM, Baker DA et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic nude mice. J. Pharmacol. Exp. Ther.291, 739–748 (1999).
   PubMed Web of Science ®Google Scholar
• Higgins B, Kolinsky K, Smith M et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs15, 503–512 (2004).
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P, Huang S, Vallabhaneni G et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res.65, 3328–3335 (2005).
   PubMed Web of Science ®Google Scholar
• Sarkaria JN, Carlson BL, Schroeder MA et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res.12, 2264–2271 (2006).
   PubMed Web of Science ®Google Scholar
• Frohna P, Lu J, Eppler S et al. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J. Clin. Pharmacol.46, 282–290 (2006).
   PubMed Web of Science ®Google Scholar
• Rakhit A, Fettner S, Riekz M et al. Clinical pharmacokinetics of erlotinib in healthy subjects. Proc. Am. Soc. Clin. Oncol.22 (2003) (Abstract 596).
   Google Scholar
• Ling J, Fettner S, Lum BL et al. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs19, 209–216 (2008).
   PubMed Web of Science ®Google Scholar
• Ling J, Johnson KA, Miao Z et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab. Dispos.34, 420–426 (2006).
   PubMed Web of Science ®Google Scholar
• Lacy CF, Armstrong LL, Goldman MP et al.Drug Information Handbook International (14th Edition). Lexi-Comp Inc., Ohio, USA (2006).
   Google Scholar
• Tarceva®, package insert. Melville, OSI Pharmaceuticals Inc., NY, USA (2007).
   Google Scholar
• Miller AA, Murry DJ, Owzar K et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J. Clin. Oncol.25, 3055–3060 (2007).
   PubMed Web of Science ®Google Scholar
• O’Bryant C, Eckhardt S, Hariharan S et al. An open-label study to characterize the pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate or moderately impaired hepatic function. Eur. J. Cancer4(Suppl.), 126–117 (2006) (Abstract 412).
   Google Scholar
• Ramanarayanan J, Scarpace SL. Acute drug induced hepatitis due to erlotinib. J. Pancreas8(1), 39–43 (2007).
   PubMedGoogle Scholar
• Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol.19, 3267–3279 (2001).
   PubMed Web of Science ®Google Scholar
• Wacker B, Nagrani T, Weinberg J et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large Phase III studies. Clin. Cancer Res.13, 3913–3921 (2007).
   PubMed Web of Science ®Google Scholar
• Malik SN, Siu LL, Rowinsky EK et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin. Cancer Res.9, 2478–2486 (2003).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353, 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Hamilton M, Wolf JL, Rusk J et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin. Cancer Res.12, 2166–2171 (2006).
   PubMed Web of Science ®Google Scholar
• Hughes AN, O’Brien M, Dunlop D et al. Phase I dose escalation pharmacokinetic study of erlotinib after failure of prior chemotherapy in patients with advanced NSCLC who continue to smoke. J. Clin. Oncol.25(Suppl. 18) 3597 (2007).
   Google Scholar
• Lu J-F, Eppler SM, Wolf J et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin. Pharmacol. Ther.80, 136–145 (2002).
   Google Scholar
• Lu J, Eppler S, Ling J et al. Clinical pharmacokinetics of erlotinib in glioblastoma multiforme patients and its implication for dosing. J. Clin. Oncol.24(suppl. 18) 2010 (2006).
   Google Scholar
• Meany HJ, Fox E, McCully C et al. The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. Cancer Chemother. Pharmacol.62, 387–392 (2008).
   Google Scholar
• Broniscer A, Panetta JC, O’Shaughnessy M et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin. Cancer Res.13, 1511–1515 (2007).
   PubMedGoogle Scholar
• Vogelbaum MA, Peereboom D, Stevens G et al. Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim results. Proc. Am. Soc. Clin. Oncol.22(Suppl. 14) 1558 (2004).
   Google Scholar
• Cloughesy T, Yung A, Vrendenberg J et al. Phase II study of erlotinib in recurrent GBM: molecular predictors of outcome. J. Clin. Oncol.22(Suppl. 16), 1507 (2004).
   Google Scholar
• Pan M, Santamaria M, Wollman DB. CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. Nat. Clin. Practice Oncol.4, 603–607 (2007).
   PubMedGoogle Scholar
• Lai CSL, Boshoff C, Falzon M et al. Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax61, 91 (2006).
   PubMedGoogle Scholar
• Popat S, Hughes S, Papadopoulos P et al. Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer56, 135–137 (2007).
   Google Scholar
• Fekrazad MH, Ravindranathan M, Jones DV Jr. Response of intracranial metastases to erlotinib therapy. J. Clin. Oncol.25, 5024–5029 (2007).
   PubMedGoogle Scholar
• Abigerges D, Khater R, Mokadem W et al. Efficacy of erlotinib in the treatment of patients with brain metastasis from non small cell lung cancer. J. Clin. Oncol.24(Suppl. 18), 17149 (2006).
   Google Scholar
• Chia SK, Chi KN, Kollmannsberger C et al. A Phase I dose escalation pharmacokinetic and pharmacodynamic study of weekly and twice weekly erlotinib in advanced stage solid malignancies. J. Clin. Oncol.25(Suppl. 18) 3594 (2007).
   Google Scholar
• Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol.24, 3831–3837 (2006).
   PubMed Web of Science ®Google Scholar
• Giaccone G, Gallegos Ruiz M, Le Chevalier T et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a Phase II study. Clin. Cancer Res.12, 6049–6055 (2006).
   PubMed Web of Science ®Google Scholar
• Jackman DM, Yeap BY, Lindeman NI et al. Phase II clinical trial of chemotherapy-naïve patients ≥ 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J. Clin. Oncol.25, 760–766 (2007).
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Chansky K, Wozniak AJ et al. Erlotinib as initial therapy in patients with advanced non-small cell lung cancer and a performance status of 2: a SWOG Phase II trial (S0341). J. Clin. Oncol.25(Suppl. 18), 7536 (2007).
   Google Scholar
• Lilenbaum R, Axelrod R, Thomas S et al. Randomized Phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J. Clin. Oncol.26, 863–869 (2008).
   PubMedGoogle Scholar
• Paz-Ares L, Sanchez JM, Garcia-Velasco A et al. A prospective Phase II trial of erlotinib in advanced non-small cell lung cancer patients with mutations in the tyrosine kinase domain of the epidermal growth factor receptor. J. Clin. Oncol.24(Suppl. 18) 7020 (2006).
   Web of Science ®Google Scholar
• Porta R, Queralt C, Cardenal F et al. Erlotinib customization based on epidermal growth factor receptor mutations in stage IV non-small-cell lung cancer patients. J. Clin. Oncol.26(Suppl.) 8038 (2008).
   Google Scholar
• Kaneko Y, Shibuya M, Nakayama T et al. Hypomethylation of c-myc and epidermal growth factor receptor genes in human hepatocellular carcinoma and fetal liver. Jpn. J. Cancer Res.76, 1136–1140 (1985).
   PubMedGoogle Scholar
• Philip PA, Mahoney MR, Allmer C et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol.23, 6657–6663 (2005).
   PubMed Web of Science ®Google Scholar
• Thomas MB, Chadha R, Glover K et al. Phase II study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer110, 1059–1067 (2007).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359, 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Allmer C et al. Phase II study of erlotinib in patients with advanced biliary cancer. J. Clin. Oncol.24, 3069–3074 (2006).
   PubMed Web of Science ®Google Scholar
• Dragovich T, McCoy S, Fenoglio-Preiser CM et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J. Clin. Oncol.24, 4922–4927 (2006).
   PubMed Web of Science ®Google Scholar
• Vincent M, Kerr I, Dingle B et al. Preliminary results from a randomized Phase II study of capecitabine versus erlotinib versus X+E in first-line metastatic colorectal cancer. Presented at: 2007 Gastrointestinal Cancers Symposium. 19–21 January, Orlando, FL, USA (2007) (Abstract 318).
   Google Scholar
• Townsley CA, Major P, Siu LL et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br. J. Cancer94, 1136–1143 (2006).
   PubMed Web of Science ®Google Scholar
• Shinojima N, Tada K, Shiraishi S et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res.63, 6962–6970 (2003).
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Abrey LE, Wen P et al. A Phase II trial of erlotinib (OSI-774) in patients with recurrent malignant gliomas not on EIAEDs. J. Clin. Oncol.22(Suppl. 14) 1502 (2004).
   Google Scholar
• Yung A, Vredenburgh J, Cloughesy T et al. Erlotinib HCL for glioblastoma multiforme in first relapse, a Phase II trial. Proc. Am. Soc. Clin. Oncol.22(Suppl. 14) 1555 (2004).
   Google Scholar
• Van Den Bent MJ, Brandes A, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or BCNU in recurrent glioblastoma multiforme: EORTC 26034. J. Oncol.25(Suppl. 18), 2005 (2007).
   Google Scholar
• Soulieres D, Senzer NN, Vokes EE et al. Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent of metastatic squamous cell cancer of the head and neck. J. Clin. Oncol.22, 77–85 (2004).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Trigo J, Hitt R et al. Open-label, uncontrolled, multicenter Phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol.25, 2171–2177 (2007).
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol.23, 8646–8654 (2005).
   PubMed Web of Science ®Google Scholar
• Garland LL, Rankin C, Gandara DR et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J. Clin. Oncol.25, 2406–2413 (2007).
   PubMed Web of Science ®Google Scholar
• Gordon AN, Finkler N, Edwards RP et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a Phase II multicenter study. Int. J. Gynecol. Cancer15, 785–792 (2005).
   PubMed Web of Science ®Google Scholar
• Oza AM, Eisenhauer EA, Elit L et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J. Clin. Oncol.26, 4319–4325 (2008).
   PubMed Web of Science ®Google Scholar
• Lestingi TM, Tolzien K, Galvez A et al. A Phase II study with single agent erlotinib in chemotherapy-naive androgen independent prostate cancer. J. Clin. Oncol.26(Suppl. 15) 16104 (2008).
   Google Scholar
• Gravis G, Goncalves A, Bladou F et al. Monocentric evaluation of erlotinib in advanced prostate cancer. J. Clin. Oncol.25(Suppl. 18), 15569 (2007).
   Google Scholar
• Dragovich T, Huberman M, Von Hoff DD et al. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: Phase IB trial. Cancer Chemother. Pharmacol.60, 295–303 (2007).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol.23, 5892–5899 (2005).
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol.25, 1545–1552 (2007).
   PubMed Web of Science ®Google Scholar
• Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 1. J. Clin. Oncol.22, 777–784 (2004).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, Schiller JS et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 2. J. Clin. Oncol.22, 785–794 (2004).
   PubMed Web of Science ®Google Scholar
• Albain KS, Green SJ, Ravdin PM et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc. Am. Soc. Clin. Oncol.21 (2002) (Abstract 143).
   Google Scholar
• Kimura T, Mahaffey CM, Pryde BJ et al. Apoptotic effects of the docetaxel-OSI-774 combination in non-small cell lung carcinoma cells. J. Clin. Oncol.22(Suppl. 14), 7143 (2004).
   Google Scholar
• Perez-Soler R, Piperdi B, Haigentz M et al. Determinants of sensitivity to the EGFR TK inhibitor erlotinib in a panel of NSCLC cell lines. J. Clin. Oncol.22(Suppl. 14), 7026 (2004).
   Google Scholar
• Davies AM, Ho C, Lara PN et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin. Lung Cancer7, 385–388 (2006).
   PubMed Web of Science ®Google Scholar
• Solit DB, She Y, Lobo J et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin. Cancer Res.11, 1983–1989 (2005).
   PubMed Web of Science ®Google Scholar
• Davies AM, Lara PN, Lau DH et al. Intermittent erlotinib in combination with docetaxel: Phase I schedules designed to achieve pharmacodynamic separation. J. Clin. Oncol.23(Suppl. 16), 7038 (2005).
   Google Scholar
• Davies AM, Ho C, Beckett L et al. Intermittent erlotinib in combination with pemetrexed: Phase I schedule designed to achieve pharmacodynamic separation. J. Clin. Oncol.26(Suppl.) 8032 (2008).
   Google Scholar
• Lee JS, Ignacio J, Yu C et al. FAST-ACT: a Phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients with stage IIIB/IV non-small cell lung cancer. J. Clin. Oncol.26(Suppl.) 8031 (2008).
   Google Scholar
• Riely GJ, Rudin CM, Kris MG et al. A randomized Phase II trial comparing pulsed erlotinib before or after carboplatin and paclitaxel in patients with stage IIIB or IV non-small cell lung cancer. J. Clin. Oncol.25(Suppl. 18), 7619 (2007).
   Google Scholar
• Davies AM, Hesketh PJ, Beckett L et al. Pharmacodynamic separation of erlotinib and docetaxel in advanced non-small cell lung cancer: overcoming hypothesized antagonism. J. Clin. Oncol.25(Suppl. 18), 7618 (2007).
   Google Scholar
• Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.25, 1960–1966 (2007).
   PubMed Web of Science ®Google Scholar
• Siu LL, Soulieres D, Chen EX et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck : a Princess Margaret Hospital Phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J. Clin. Oncol.25, 2178–2183 (2007).
   PubMed Web of Science ®Google Scholar
• Kim ES, Kies MS, Glisson BS et al. Final results of a Phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. J. Clin. Oncol.25(Suppl. 18), 6013 (2007).
   Google Scholar
• Vincent M, Kerr I, Dingle B et al. Capecitabine (X) compared to X + erlotinib as first-line treatment in patients with metastatic colorectal cancer: interim efficacy results from a randomized Phase II study. J. Clin. Oncol.25(Suppl. 18), 14560 (2007).
   Google Scholar
• Meyerhardt JA, Stuart K, Fuchs CS et al. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastatic colorectal cancer. J. Clin. Oncol.24, 1892–1897 (2006).
   PubMed Web of Science ®Google Scholar
• Kaur H, Silverman P, Singh D et al. Toxicity and outcome data in a Phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer. J. Clin. Oncol.24(Suppl. 18), 10623 (2006).
   Google Scholar
• Graham DL, Hillman DW, Hobday TJ et al. N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or-second line therapy for metastatic breast cancer. J. Clin. Oncol.23(Suppl. 16), 644 (2005).
   Google Scholar
• Wu H, Kim J, Cao Q et al. Combined modality therapy of NCI-H460 human lung cancer using epidermal growth factor receptor inhibitor, OSI-774, and ionizing radiation in vitro and in vivo. Int. J. Rad. Oncol. Biol. Phys.54 (2002) (Abstract 1031).
   Google Scholar
• Krishnan S, Brown PD, Ballman KV et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group Protocol N0177. Int. J. Radiation Oncol. Biol. Phys.65, 1192–1199 (2006).
   PubMed Web of Science ®Google Scholar
• Geoerger B, Hargrave D, Ndiaye A et al. ITCC Phase I study of erlotinib as single agent in children with refractory and relapsed malignant brain tumors and in combination with irradiation in newly diagnosed brain stem glioma. J. Clin. Oncol.25(Suppl.18), 9556 (2007).
   Google Scholar
• Broniscer A, Baker SJ, Merchant TE et al. Phase I study of erlotinib adminstered concurrently with and after irradiation in the treatment of children, adolescents, and young adults with newly diagnosed intracerebral high-grade glioma. J. Clin. Oncol.25(Suppl. 18), 9553 (2007).
   Google Scholar
• Hoffman PC, Mauer AM, Haraf DC et al. A Phase I study of erlotinib in combination with chemoradiation for unresectable, locally advanced non-small cell lung cancer. J. Clin. Oncol.23(Suppl. 16), 7113 (2005).
   Google Scholar
• Mekhail T, Rice T, Murthy S et al. Phase I trial of neoadjuvant and postoperative paclitaxel, carboplatin, and erlotinib with concurrent accelerated hyperfractionation radiation (AHFR) followed by erlotinib maintenance therapy in stage III non-small cell lung cancer. J. Clin. Oncol.23(Suppl. 16), 2091 (2005).
   Google Scholar
• Duffy A, Kortmansky J, Schwartz GK et al. A Phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann. Oncol.19, 86–91 (2008).
   PubMedGoogle Scholar
• Iannitti D, Dipetrillo T, Akerman P et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a Phase I study. Am. J. Clin. Oncol.28, 570–575 (2005).
   PubMed Web of Science ®Google Scholar
• Cardenes HR, Chiorean EG, Perkins S et al. Neoadjuvant gemcitabine, erlotinib, and hypofractionated radiation therapy for potentially resectable pancreatic cancer: a pilot study. J. Clin. Oncol.26(Suppl.), 15578 (2008).
   Google Scholar
• Savvides P, Agarwala S, Greskovich J et al. Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck. J. Clin. Oncol.24(Suppl. 18), 5545 (2006).
   PubMedGoogle Scholar
• Rodrigues AN, do Carmo CC, Viegas C et al. Erlotinib, cisplatin, and radiotherapy for patients with locally advanced squamous cell cervical cancer: a Phase I trial. Proc. Am. Soc. Clin. Oncol.25 (2007) (Abstract 5592).
   Google Scholar
• Dobelbower MC, Russo SM, Raisch KP et al. Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin, and radiotherapy for patients with esophageal cancer: a Phase I study. Anticancer Drugs17, 95–102 (2006).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350, 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Sandler AB, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355, 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol.23, 2544–2555 (2005).
   PubMed Web of Science ®Google Scholar
• Herbst RS, O’Neill VJ, Fehrenbacher L et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J. Clin. Oncol.25, 4743–4750 (2007).
   PubMed Web of Science ®Google Scholar
• Ko AH, Dito E, Schillinger B et al. A Phase II study of bevacizumab plus erlotinib in patients with gemcitabine-refractory metastatic pancreatic cancer. Proc. Am. Soc. Clin. Oncol.26 (2008) (Abstract 4516).
   Google Scholar
• Gomez-Martin C, Camara JC, Rubio B et al. A Phase I study of erlotinib, bevacizumab, and gemcitabine in patients with advanced pancreatic cancer. GI Cancer Symposium J. Clin. Oncol.25(Suppl. 18), 4611 (2008).
   Google Scholar
• Starling N, Watkins D, Chau I et al. A Phase I study of a chemotherapy doublet (gemcitabine plus capecitabine), combined with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma: the TARGET trial. Presented at: 2008 Gastrointestinal Cancers Symposium. Orlando, FL USA, 25–27 January 2008 (Abstract 141).
   Google Scholar
• Kindler HL, Gangadhar T, Karrison T et al. Final analysis of a randomized Phase II study of bevacizumab and gemcitabine plus cetuximab or erlotinib in patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol.26 (2008) (Abstract 4502).
   Google Scholar
• Vervenne W, Bennouna J, Humblet Y et al. A randomized, double-blind, placebo controlled, multicenter Phase III trial to evaluate the efficacy and safety of adding bevacizumab to erlotinib and gemcitabine in patients with metastatic pancreatic cancer. Proc. Am. Soc. Clin. Oncol.26 (2008) (Abstract 4507).
   Google Scholar
• Holen KD, Mahoney MR, LoConte NK et al. Efficacy report of a multicenter Phase II trial testing a biologic-only combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a Phase II Consortium study. Proc. Am. Soc. Clin. Oncol.26 (2008) (Abstract 4522).
   Google Scholar
• Thomas MB, Chadha R, Iwasaki M et al. The combination of bevacizumab and erlotinib shows significant biological activity in patients with advanced hepatocellular carcinoma. Proc. Am. Soc. Clin. Oncol.25 (2007) (Abstract 4567).
   Google Scholar
• Vokes EE, Cohen EE, Mauer AM et al. A Phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol.23 (2005) (Abstract 5503).
   Google Scholar
• Meyerhardt JA, Stuart K, Fuchs CS et al. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann. Oncol.18, 1185–1198 (2007).
   PubMed Web of Science ®Google Scholar
• Spigel DR, Hainsworth JD, Burris HA III et al. Phase II study of FOLFOX4, bevacizumab, and erlotinib as first-line therapy in patients with advanced colorectal cancer. Presented at: 2008 Gastrointestinal Cancers Symposium. Orlando, FL, USA, 25–27 January, 2008 (Abstract 238).
   Google Scholar
• Dickler M, Rugo H, Caravelli J et al. Phase II trial of erlotinib (OSI-774), and epidermal growth factor receptor-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor, in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol.22 (2004) (Abstract 2001).
   Google Scholar
• Wyman K, Spigel D, Puzanov I et al. A multicenter Phase II study of erlotinib and bevacizumab in patients with metastatic melanoma. Proc. Am. Soc. Clin. Oncol.25 (2007) (Abstract 8539).
   Google Scholar
• Papadimitrakopoulou V, Blumenschein G, Leighl NB et al. A Phase I/II study investigating the combination of RAD001 (everolimus) and erlotinib as 2nd and 3rd line therapy in patients with advanced non-small cell lung cancer previously treated with chemotherapy: Phase I results. Proc. Am. Soc. Clin. Oncol.26 (2008) (Abstract 8051).
   Google Scholar
• Bendell JC, George D, Nixon A et al. Results of a Phase I study of bevacizumab, everolimus, and erlotinib in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol.25 (2007) (Abstract 3548).
   Google Scholar
• Robins HI, Wen PY, Chang SM et al. Phase I study of erlotinib and CCI-779 for patients with recurrent malignant gliomas (NABTC 04–02). Proc. Am. Soc. Clin. Oncol.25 (2007) (Abstract 2057).
   Google Scholar
• Huang S, Armstrong EA, Benavente S et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res.64, 5355–5362 (2004).
   PubMed Web of Science ®Google Scholar
• Preston GG, Calvo E, Papadopoulos K et al. Multi-targeted inhibition of the epidermal growth factor and vascular endothelial growth factor receptor pathways: a Phase I study of cetuximab, erlotinib, and bevacizumab in patients with solid tumors. Proc. Am. Soc. Clin. Oncol.24 (2006) (Abstract 3005).
   Google Scholar
• Tan AR, Steinberg SM, Parr AL et al. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment. Ann. Oncol.19, 185–190 (2008).
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Delord JP, Halpern A et al. HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist10, 345–356 (2005).
   PubMed Web of Science ®Google Scholar
• Oishi KJ, Garey JS, Burke B et al. Managing cutaneous side effects associated with erlotinib in head and neck cancer and non-small cell lung cancer patients. Proc. Am. Soc. Clin. Oncol.24 (2006) (Abstract 18538).
   Google Scholar
• Rhee J, Oishi K, Garey J et al. Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents. Clin. Colorectal Cancer5(Suppl. 2), S101–S106 (2005).
   PubMedGoogle Scholar
• Hu JC, Sadeghi P, Pinter-Brown LC et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J. Am. Acad. Dermatol.56, 317–326 (2007).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Kim ES, Eaby B et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist12, 610–621 (2007).
   PubMed Web of Science ®Google Scholar
• Ando M, Okamoto I, Yamamoto N et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol.24, 2549–2556 (2006).
   PubMed Web of Science ®Google Scholar
• Clark GM, Zborowski DM, Santabarbara P et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Clin. Lung Cancer7, 389–394 (2006).
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol.22, 3238–3247 (2004).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl Cancer Inst..97, 643–655 (2005).
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Cappuzzo F et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann. Oncol.18, 752–760 (2007).
   PubMed Web of Science ®Google Scholar
• Tsao M-S, Sakurada A, Cutz, J-C et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N. Engl. J. Med.353, 133–144 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu C-Q, da Cunha Santos G, King K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol.26, 4268–4275 (2008).
   PubMed Web of Science ®Google Scholar
• Ahn M, Ahn J, Kim S et al. Correlation of the EGFR gene mutation, gene amplification and protein expression in non-small cell lung cancer with clinical outcomes of erlotinib monotherapy: an exploratory analysis of biomarkers by the Korean Cancer Study Group. Proc. Am. Soc. Clin. Oncol.25 (2007) (Abstract 7608).
   Google Scholar
• Moscatello DK, Holgado-Madruga M, Emlet DR et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem.273, 200–206 (1998).
   PubMed Web of Science ®Google Scholar
• Voldborg BR, Damstrup L, Spang-Thomsen M et al. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann. Oncol.8, 1197–1206 (1997).
   PubMed Web of Science ®Google Scholar
• Nishikawa R, Ji XD, Harmon RC et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl Acad. Sci. USA91, 7727–7731 (1994).
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst.97, 339–346 (2005).
   PubMed Web of Science ®Google Scholar
• Toyooka S, Matsuo K, Shigematsu H et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non-small cell lung cancer. Clin. Cancer Res.13, 5763–5768 (2007).
   PubMedGoogle Scholar
• Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol.23, 5900–5909 (2005).
   PubMed Web of Science ®Google Scholar
• Kwak EL, Jankowski J, Thayer SP et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin. Cancer Res.12, 4283–4287 (2006).
   PubMed Web of Science ®Google Scholar
• Barber TD, Vogelstein B, Kinzler KW et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med.351, 2883 (2004).
   PubMed Web of Science ®Google Scholar
• Lee J, Jang K-T, Ki C-S et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival in pancreatic adenocarcinoma. Cancer109, 1561–1569 (2007).
   PubMed Web of Science ®Google Scholar
• Jackman D, Lindeman NI, Lucca J et al. Phase II study of erlotinib in chemo-naive women with advanced pulmonary adenocarcinoma. Proc. Am. Soc. Clin. Oncol.25 (2007) (Abstract 7591).
   Google Scholar
• Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res.13, 2890–2896 (2007).
   PubMed Web of Science ®Google Scholar
• Jackman DM, Sequist LV, Cioffredi L et al. Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib. Proc. Am. Soc. Clin. Oncol.26 (2008) (Abstract 8035).
   Google Scholar
• Thomson S, Buck E, Petti F et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res.65, 9455–9462 (2005).
   PubMed Web of Science ®Google Scholar
• Reckamp KL, Gardner BK, Figlin RA et al. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J. Thoracic Oncol.3, 117–124 (2008).
   Google Scholar
• Savic S, Tapia C, Grilli B et al. Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br. J. Cancer98, 154–160 (2008).
   Google Scholar
• Mack PC, Holland WS, Burich RA et al. Predictive value of EGFR and KRAS mutations detected in plasma from non-small cell lung cancer patients treated with docetaxel and intermittent erlotinib. Proc. Am. Soc. Clin. Oncol.26 (2008) (Abstract 8062).
   Google Scholar
• Kuang Y, Rogers A, Wang L et al. Non-invasive detection of EGFR T790M in gefitinib/erlotinib resistant NSCLC. Proc. Am. Soc. Clin. Oncol.26 (2008) (Abstract 8075).
   Google Scholar
• Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med.359, 366–377 (2008).
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib and erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med.2, E73 (2005).
   PubMed Web of Science ®Google Scholar
• Kwak EL, Sordella R, Bell DW et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Nat. Acad. Sci. USA102, 7665–7770 (2005).
   PubMed Web of Science ®Google Scholar
• Taguchi F, Solomon B, Gregorc V et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J. Natl Cancer Inst.99, 838–846 (2007).
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.352, 786–792 (2005).
   PubMed Web of Science ®Google Scholar
• Yun C-H, Mengwasser KE, Toms AV et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA105, 2070–2075 (2008).
   PubMed Web of Science ®Google Scholar
• Bean J, Brennan C, Shih J-Y et al.MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl Acad. Sci. USA104, 20932–20937 (2007).
   PubMed Web of Science ®Google Scholar
• Yang C, Shih J, Chao T et al. Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: preliminary results of a single-arm Phase II clinical trial. Proc. Am. Soc. Clin. Oncol.26 (2008) (Abstract 8026).
   Google Scholar
• Janne PA, Schellens JH, Engelman JA et al. Preliminary activity and safety results from a Phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients with NSCLC. Proc. Am. Soc. Clin. Oncol.26 (2008) (Abstract 8027).
   Google Scholar
• Miller VA, Wakelee HA, Lara PN et al. Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: preliminary results of a Phase II trial. Proc. Am. Soc. Clin. Oncol.26 (2008) (Abstract 8028).
   Google Scholar